Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis

The Lancet Infectious Diseases

Volumn 11, Issue 11, 2011, Pages 834-844

  Tasina, Efthimia ^a   Haidich, Anna Bettina ^b   Kokkali, Stamatia ^b   Arvanitidou, Malamatenia ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTRIAXONE; CILASTATIN; DELAFLOXACIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; SULBACTAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT DISEASE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HOSPITAL INFECTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; SKIN INFECTION; TREATMENT OUTCOME; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82455187892     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70177-3     Document Type: Article

References (90)

1. Kanj SS, Kanafani ZA Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011, 86:250-259.
2. Eckmann C, Dryden M Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010, 15:554-563.
3. Prescribing information for Tygacil (tigecycline) Wyeth, (accessed April 17, 2011). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf.
4. Doan TL, Fung HB, Mehta D, Riska PF Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006, 28:1079-1106.
5. Townsend ML, Pound MW, Drew RH Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006, 60:1662-1672.
6. Noskin GA Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005, 41:S303-S314.
7. Garrison MW, Neumiller JJ, Setter SM Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther 2005, 27:12-22.
8. Greer ND Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006, 19:155-161.
9. Falagas ME, Karageorgopoulos DE, Dimopoulos G Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009, 10:13-21.
10. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49:220-229.
11. Rodvold KA, Gotfried M, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
12. Peterson LR Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis 2005, 52:163-164.
13. Conte JE, Golden JA, Kelly MG, Zurlinden E Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005, 25:523-529.
14. Pieracci FM, Barie PS Intra-abdominal infections. Curr Opin Crit Care 2007, 13:440-449.
15. Niederman MS Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Antimicrob Agents Chemother 2006, 42:S72-S81.
16. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005, 3:35-47.
17. Maclayton DO, Hall RG Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007, 41:235-244.
18. Mills K, Nelson AC, Winslow BT, Springer KL Treatment of nursing home-acquired pneumonia. Am Fam Physician 2009, 79:976-982.
19. Townsend ML, Pound MW, Drew RH Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections. Ther Clin Risk Manag 2007, 3:1059-1070.
20. Esposito S, Noviello S, Leone S Skin and soft tissue infections: current therapeutic options. Infez Med 2008, 16:65-73.
21. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:329-338.
22. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008, 52:204-210.
23. Mallick R, Sun S, Schell SR Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) 2007, 8:159-172.
24. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41:S354-S367.
25. Petersen PJ, Ruzin A, Tuckman M, Jones CH In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis 2010, 66:407-418.
26. Peterson LR A review of tigecycline-the first glycylcycline. Int J Antimicrob Agents 2008, 32(suppl 4):S215-S222.
27. Vergidis PI, Falagas ME New antibiotic agents for bloodstream infections. Int J Antimicrob Agents 2008, 32(suppl 1):S60-S65.
28. Townsend ML Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006, 60:1662-1672.
29. Bhattacharya M, Parakh A, Narang M Tigecycline. J Postgrad Med 2009, 55:65-68.
30. Schafer JJ, Goff DA Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6:557-567.
31. Shakil S, Akram M, Khan AU Tigecycline: a critical update. J Chemother 2008, 20:411-419.
32. Mullangi PK, Pankey GA Tigecycline in critical care. Crit Care Clin 2008, 24:365-375.
33. Rose WE, Rybak MJ Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006, 26:1099-1110.
34. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
35. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
36. Gardiner D, Dukart G, Cooper A, Babinchak T Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010, 50:229-238.
37. Cai Y, Wang R, Liang B, Bai N, Liu Y Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55:1162-1172.
38. Ioannidis JP, Karassa F The need to consider the wider agenda in systematic reviews and meta-analyses. BMJ 2010, 341:762-765.
39. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62:1-34.
40. Robinson KA, Dickersin K Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002, 31:150-153.
41. Cochrane handbook for systematic reviews of interventions version 5.1.0 2011, Cochrane Collaboration, (accessed March 28, 2011). http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
42. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
43. Barza M, Trikalinos TA, Lau J Statistical considerations in meta-analysis. Infect Dis Clin North Am 2009, 23:195-210.
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
45. Galbraith RF A note on graphical presentation estimated odds ratios from several clinical trials. Stat Med 1988, 7:889-894.
46. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008, 61:991-996.
47. Rücker G, Schwarzer G, Carpenter J Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med 2008, 27:746-763.
48. McGovern P, Leister N, Zito E, Tucker N, Mansfield D, Babinchak T Efficacy of tigecycline versus ceftriaxone and metronidazole for complicated intra-abdominal infections-analysis of pooled clinical trial data. Clin Microbiol Infect 2010, 16(suppl 2):S448.
49. Babinchak T, Ellis-Grosse EJ, Dartois N, Rose GM, Loh E The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(suppl 5):S354-S367.
50. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose GM, Loh E The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(suppl 5):S341-S353. Tigecycline 300 and 305 cSSSI Study Groups.
51. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:329-338.
52. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T Efficacy of tigecycline versus ceftriaxone and metronidazole for complicated intra-abdominal infections: Americas study 400. Clin Microbiol Infect 2009, 15(suppl 4):S182.
53. Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N The efficacy and safety of tigecycline for the treatment of complicated intra-adominal infections-the European experience. J Chemother 2008, 20(suppl 1):S12-S19.
54. Teras J, Gardovskis J, Vaasna T, Kupcs U, Pupelis G, Dartois N Overview of tigecycline efficacy and safety in the treatment of complicated skin and structure infections-a European perspective. J Chemother 2008, 20(suppl 1):S20-S27.
55. Dartois N, Castaing N, Gandjini H, Cooper A Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008, 20(suppl 1):S28-S35.
56. McGovern P, Rill D, Zito E, Babinchak T Efficacy of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate to treat complicated skin and skin structure infections-study 900. Clin Microbiol Infect 2010, 16(suppl 2):S448.
57. O'Riordan W, Surber J, Manos P, et al. Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections. Clin Microbiol Infect 2009, 15(suppl 4):S519.
58. Mallick R, Sun S, Schell SR Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) 2007, 8:159-171.
59. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004, 26:704-714.
60. Chuang YC, Chang CM, Aradhya S, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. J Microbiol Immunol Infect 2011, 44:116-124.
61. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49:4658-4666.
62. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744]. BMC Infect Dis 2005, 5:88. the 301 Study Group.
63. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(suppl 1):i17-i28. on behalf of the 307 Study Group.
64. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009, 9:44.
65. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009, 63:52-61.
66. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010, 16:1274-1281.
67. Chen Z, Wu J, Zhang Y, et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010, 10:21.
68. Freire AT, Melnykb V, Kimc MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68:140-151.
69. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9:251-261.
70. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Infect Dis 2005, 3:35-47.
71. Simpson E The interpretation of interaction in contingency tables. J R Stat Soc Series B 1951, 13:238-241.
72. Altman DG, Deeks JJ Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002, 2:3.
73. Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 2009, 34:486-489.
74. FDA drug safety commnication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections (Sept 1, 2010) US Food and Drug Administration, (accessed April 18, 2011). http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
75. Mc Govern P, Wible M, El-Tahtawy A, Biswas P, Meyer D Mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Crit Care Med 2010, 38:A81.
76. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T Reporting bias in m edical research-a narrative review. Trials 2010, 11:37.
77. Al-Marzouki S, Roberts I, Evans S, Marshall T Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet. Lancet 2008, 372:201.
78. Haidich AB, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol 2011, 64:124-135.
79. Yang K, Guglielmo BJ Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother 2007, 41:1427-1435.
80. Woodford N, Hill RL, Livermore DM In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 2007, 59:582-583.
81. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
82. Ergin A, Köseoglu O, Hascnullelik G Multidrug-resistant Acinetobacter baumannii blood isolates: in vitro activity of colistin and tigecycline, existence of metallo-β-lactamase production and heteroresistance. Clin Microbiol Infect 2010, 16:S207.
83. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46:567-570.
84. Schafer JJ, Goff DA, Stevenson KB, Mangino JE Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007, 27:980-987.
85. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007, 27:1198-1201.
86. Vasilev K, Reshedko G, Orasan R, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62:S29-S40.
87. Rennie D Trial registration: a great idea switches from ignored to irresistible. JAMA 2004, 292:1359-1362.
88. Laine C, Horton R, DeAngelis CD, et al. Clinical trial registration: looking back and moving ahead. Lancet 2007, 369:1909-1911.
89. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
90. Wang JL, Hsueh PR Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009, 10:785-796.